Zydus Cadila gets tentative nod from USFDA to market Parkinson's disease drug

The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market the capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, Zydus Cadila said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3gjkGz1
via IFTTT